Holly Jackson


The Case for Response Adaptive Trial Design for Rare Diseases

June 27, 2019

As pharma businesses shift their focus away from ‘blockbusters’ to treatments for rare diseases, clinical trial design must also go through a period of change and should consider response-adaptive over traditional randomized controlled trial designs.